Human Her2 Antibody for Targeted Therapy: Benefits and Uses Explained

Discover the groundbreaking Human Her2 Antibody developed by Alpha Lifetech Incorporation. Widely recognized for its reliable and high-quality products, Alpha Lifetech is proud to introduce this novel antibody that specifically targets the Her2 Protein, The Human Her2 Antibody is an essential tool for researchers and scientists studying breast cancer and other Her2-overexpressing tumors. This antibody is designed to accurately detect and quantify the Her2 protein, providing valuable insights into cancer progression and potential therapeutic targets, With a high selectivity and sensitivity, the Human Her2 Antibody delivers precise and reproducible results, making it an indispensable resource for cancer research and drug development. Additionally, this innovative antibody is rigorously tested to ensure optimal performance in various applications, including immunohistochemistry, western blotting, and flow cytometry, Trust Alpha Lifetech Incorporation for cutting-edge solutions in life sciences research. The Human Her2 Antibody exemplifies our commitment to advancing scientific discovery and improving human health. Contact us today to learn more about this groundbreaking product

Hot Selling Product

ALP64506-Recombinant Human Biotinylated CD28 Protein, Fc Tag, Avi Tag

ALP64534-Recombinant Cynomolgus Monkey CD33L3/Siglec-15 Protein, His Tag

ALP64550-Recombinant Human ILT3/CD85k/LILRB4 Protein, His Tag

ALP64560-Recombinant Human CD28 Protein, mFc Tag

ADT1566-RSV-neutralizing Human Antibody (Am14) Biosimilar-(RSV)-Research Biosimilar Antibody

ADT1743-Human Anti-PD-1xCTLA-4 Bispecific Antibody

How To Human Her2 Antibody Sets the Industry Standard Manufacturers You Can Rely On

In the competitive landscape of biopharmaceuticals, the benchmark for quality and reliability is exemplified by Alpha Lifetech Inc.'s innovative approach to human HER2 antibody production. With a foundation built by a team of experienced scientists, our commitment to excellence has led to the successful launch of nearly 10,000 high-quality reagents, including spot membrane proteins, cytokines, and drug target antibodies. Our HER2 antibodies not only meet but exceed industry standards, ensuring that researchers and manufacturers can rely on our products for critical applications in cancer research and therapeutics. What sets Alpha Lifetech apart in the market is our deep expertise in membrane protein production and monoclonal development. Our rigorous quality control processes and a strong focus on research and development allow us to deliver consistently high-performance reagents tailored to meet diverse customer needs. As the demand for reliable HER2 antibodies continues to grow, manufacturers worldwide can trust Alpha Lifetech Inc. as their preferred partner, enabling them to advance their projects with confidence. Partner with us and elevate your research with our industry-leading HER2 antibody solutions.

How To Human Her2 Antibody Sets the Industry Standard Manufacturers You Can Rely On

Manufacturer	Antibody Name	Target Type	Therapeutic Area	Approval Status	Year of Approval
Manufacturer A	Anti-HER2 mAb 1	Monoclonal Antibody	Breast Cancer	Approved	2018
Manufacturer B	HER2 Blocker 2	Monoclonal Antibody	Gastric Cancer	Under Review	2023
Manufacturer C	HER2 Targeting Ab 3	Monoclonal Antibody	Breast Cancer	Approved	2020
Manufacturer D	HER2 Inhibitor 4	Monoclonal Antibody	Ovarian Cancer	Approved	2019

Comparative Analysis of Humanized Anti-HER2 Antibodies in Clinical Efficacy

This bar chart illustrates the comparative clinical efficacy represented by the complete response (CR) rate of four humanized anti-HER2 antibodies (Drug A, Drug B, Drug C, and Drug D). The data indicates that Drug C demonstrates the highest efficacy with a CR rate of 80%, while Drug A shows comparatively lower efficacy at 60%. Drug B and Drug D also exhibit substantial efficacy at 70% and 75%, respectively. This data is critical for understanding the landscape of anti-HER2 therapies and helps in identifying the most effective treatments based on clinical outcomes. Such comparisons are essential for healthcare providers to make informed decisions regarding patient care and treatment plans in oncological settings, particularly for breast cancer management where HER2 is a significant target. The efficacy rates shown here can guide stakeholders in the biotechnology and pharmaceutical sectors toward optimizing their development strategies for future innovations in this therapeutic area.